Eric Mueller, MD
Rheumatology · Spokane, WANPI 1912017203
Payments from drug & device makers
Across 800 payments — averaging $3758.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2.2M
- AbbVie$273K
- Eli Lilly$188K
- Sun Pharmaceutical Industries Inc.$187K
- UCB SA$93K
- Gilead$7K
- plus $10K from 28 others
Across 1 payment — averaging $321.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$321
What the payments were for
- Consulting fees$5,32037%
- Travel & lodging$7966%
- Food & beverage$8,08357%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 143 | $2,249,600 |
| AbbVie | 148 | $273,348 |
| Eli Lilly | 39 | $187,827 |
| Sun Pharmaceutical Industries Inc. | 231 | $187,060 |
| UCB SA | 13 | $92,621 |
| Gilead | 12 | $6,510 |
| Sanofi US Services Inc. | 5 | $5,108 |
| Novartis | 34 | $1,084 |
| Lilly USA, LLC | 34 | $855 |
| AstraZeneca | 23 | $456 |
| Genentech USA, Inc. | 29 | $402 |
| UCB, Inc. | 23 | $392 |
| GSK | 19 | $320 |
| Johnson & Johnson | 8 | $167 |
| Pfizer | 8 | $114 |
| Sanofi | 4 | $108 |
| E.r. Squibb & Sons, L.L.C. | 4 | $57 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $54 |
| Bristol Myers Squibb | 2 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $36 |
| Boehringer Ingelheim | 1 | $31 |
| Ferring Pharmaceuticals Inc. | 2 | $31 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $29 |
| Fresenius Kabi USA, LLC | 1 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Sobi, Inc | 1 | $23 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Pharming Healthcare, Inc. | 1 | $19 |
| Zimmer Biomet | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Inova Diagnostics, Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
| Sandoz | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$150
How this compares
$3,006,468 in reported general payments places this provider in the 95th percentile of 157 rheumatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 72 | $598,044 |
| Enbrel SureclickEtanercept | 62 | $464,188 |
| RinvoqUpadacitinib | 56 | $376,331 |
| Xeljanz XrTofacitinib Citrate | 39 | $247,012 |
| Humira PenAdalimumab | 13 | $165,730 |
| Cosentyx Sensoready PenSecukinumab | 14 | $127,659 |
| EnbrelEtanercept | 13 | $102,625 |
| Enbrel MiniEtanercept | 13 | $97,777 |
| Humira(Cf)Adalimumab | 14 | $95,845 |
| Orencia ClickjectAbatacept | 16 | $86,725 |
| OtezlaApremilast | 11 | $52,501 |
| Hydroxychloroquine Sulfate | 385 | $17,876 |
| MethotrexateMethotrexate Sodium | 480 | $9,706 |
| Mycophenolate Mofetil | 70 | $8,863 |
| Colchicine | 39 | $3,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $273,348 | $472,17570 claims |
| AmgenEnbrel, Otezla | $2,249,600 | $155,12624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 157 rheumatology providers in Washington.
Other rheumatology in Spokane
- Howard KenneySpokane$1.3M
- Sean LasalleSpokane$982K
- Jeffrey ButlerSpokane$507K
- Michael CoanSpokane$169K
- Rebecca MunteanSpokane$146K
- Usman AjazSpokane$11K
- Barbara JacobsSpokane$5K
- Penny SatherSpokane$4K
- Raksha PradhanSpokane$2K
- Philip MeaseSeattle$5.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.